United Kingdom

People: Chimerix Inc (CMRX.OQ)

CMRX.OQ on NASDAQ Stock Exchange Global Market

17 Jun 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Lanier, Randall 

Dr. Randall Lanier, Ph.D., serves as Chief Science Officer of the Company. During his tenure at Chimerix, Dr. Lanier has led teams that designed successful studies of brincidofovir for smallpox, characterized the resistance/activity profile of brincidofovir for multiple viruses, and explored the potential of the Chimerix chemical library to address unmet medical needs. Recently these efforts led to the identification of a clinical candidate, CMX521, for norovirus, the leading cause of viral gastroenteritis worldwide. Dr. Lanier has nearly 25 years of experience in the discovery and development of antivirals; he has focused much of his career on understanding the activity, mechanism, and resistance profiles of nucleoside analogs used for prevention and treatment of viral disease caused by HIV, CMV, adenovirus and poxviruses. Prior to joining Chimerix in 2007, Dr. Lanier held positions of increasing leadership at Burroughs Wellcome, GlaxoWellcome, and GlaxoSmithKline, where he supervised a clinical virology/immunology laboratory, led teams for drug discovery and licensing opportunity evaluation, served as the clinical virologist on several projects (three approved NDAs), and supported product differentiation and post-marketing activities. Dr. Lanier holds a B.A. in Biology from New College in Sarasota, Florida, and a PhD in Cellular and Molecular Biology from the University of Texas Health Science Center in San Antonio, Texas.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --